Status:
COMPLETED
Omega-3 Hydrogel and Prevention of Oral Mucositis
Lead Sponsor:
Basma Morsy
Conditions:
Mucositis Oral
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Oral mucositis (OM) is recognized as one of the most frequent debilitating sequela encountered by head and neck cancer (HNC) patients treated by radiotherapy. The objective of the study is to assess p...
Eligibility Criteria
Inclusion
- Patients who are going to receive radiotherapy as a treatment of head and neck cancer either as postoperative (adjuvant) therapy or definitive therapy.
- Patients whose radiotherapy treatment planned dose is 50 Gy or above
- Males and females with an age not less than 18 years
- Patients receiving radiotherapy alone or receiving concomitant cisplatin (or carboplatin) with radiotherapy.
Exclusion
- Patients under Anticoagulants such as warfarin, heparin, or aspirin.
- Patients suffering from any uncontrolled systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction)
- Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.
Key Trial Info
Start Date :
February 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05214495
Start Date
February 9 2022
End Date
September 1 2022
Last Update
January 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Dentistry Alexandria University
Alexandria, Egypt